Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
ORIC Pharmaceuticals, focused on overcoming cancer resistance, will present a company overview at two upcoming conferences. Jacob Chacko, M.D., CEO, will deliver an on-demand presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and a live presentation at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Webcasts of both events will be accessible on the company’s website for 90 days. ORIC’s lead product, ORIC-101, targets glucocorticoid resistance in solid tumors and is currently in Phase 1b trials.
ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in two investor conferences in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day features a virtual fireside chat on February 11 at 1:00 p.m. ET, while the LifeSci Partners Precision Oncology Day will host investor meetings on February 17. A live webcast of the fireside chat will be available on their website for 90 days post-event. ORIC focuses on developing therapies addressing cancer resistance mechanisms, with notable candidates including ORIC-101, ORIC-533, ORIC-944, and ORIC-114.
ORIC Pharmaceuticals (Nasdaq: ORIC) has outlined significant developments for 2021, focusing on clinical programs and pipeline expansion. Key highlights include the ongoing enrollment for ORIC-101 trials, with initial readouts anticipated this year. The company plans to submit three IND applications for ORIC-533, ORIC-944, and ORIC-114. Financially, ORIC reported $293.6 million in cash at the end of 2020, sufficient to fund operations into the second half of 2023. Jacob Chacko, CEO, emphasized these advancements position ORIC for a dynamic year ahead.
ORIC Pharmaceuticals, a clinical stage oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Jacob Chacko will provide an overview of the company, which is focused on overcoming therapeutic resistance in cancer treatments. Their lead candidate, ORIC-101, is currently in Phase 1b trials for metastatic prostate cancer and advanced solid tumors in combination with Xtandi and Abraxane, respectively. A live webcast of the presentation will be available on their website.
ORIC Pharmaceuticals announced the initiation of Part II expansion of the Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, combined with Abraxane for treating advanced solid tumors. This stage will enroll up to 132 patients with pancreatic ductal adenocarcinoma, ovarian cancer, triple-negative breast cancer, and others. The recommended Phase 2 dose was found to be 160 mg of ORIC-101 with 75 mg/m² of Abraxane. The trial aims to address significant unmet medical needs in these cancer types.
ORIC Pharmaceuticals announced the completion of its underwritten public offering of 5,796,000 shares, raising approximately $133.3 million. This includes the full exercise of the underwriters’ option to purchase an additional 756,000 shares, priced at $23.00 each. The offering was managed by J.P. Morgan, Citigroup, Jefferies, and Guggenheim. Funds will support ORIC's pipeline, including its lead candidate ORIC-101, aimed at combating cancer therapeutic resistance.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced a public offering of 5,040,000 shares of common stock, priced at $23.00 per share, aiming to raise approximately $115.9 million. The underwriters have a 30-day option to purchase an additional 756,000 shares. The offering is slated to close on November 17, 2020, pending customary conditions. J.P. Morgan, Citigroup, Jefferies, and Guggenheim are the joint book-running managers for this offering, which is intended to bolster ORIC's pipeline for cancer therapeutics, specifically targeting resistance mechanisms.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced a public offering of 4,000,000 shares of its common stock, with plans to grant underwriters a 30-day option for an additional 600,000 shares. The offering, subject to market conditions, is underwritten by J.P. Morgan, Citigroup, Jefferies, and Guggenheim Securities. A registration statement has been filed with the SEC, but the offering is contingent upon its effectiveness. ORIC focuses on developing treatments for therapeutic resistance in cancer, including lead candidate ORIC-101 currently in Phase 1b trials.
The press release from ORIC Pharmaceuticals, a clinical stage oncology company, highlights CEO Jacob Chacko's participation in two upcoming investor conferences in November 2020. The events include a virtual fireside chat at the Jefferies Virtual London Healthcare Conference on November 18 and meetings at the SVB Leerink Oncology 1x1 Day on November 19. A live webcast of the fireside chat will be accessible on the company’s website, with a replay available for 90 days. ORIC is focused on developing therapies to combat therapeutic resistance in cancer.
ORIC Pharmaceuticals, a clinical-stage oncology firm, reported Q3 2020 financial results, highlighting progress in its oncology pipeline. The company secured licenses for the EGFR/HER2 inhibitor (ORIC-114) and PRC2 inhibitor (ORIC-944), with expectations to file IND applications for multiple programs in 2021. Significant milestones anticipated include interim data readouts for ORIC-101 and initiation of trials for ORIC-114. Financially, cash reserves stand at $186.6 million, expected to sustain operations into H2 2022, though R&D and G&A expenses have risen significantly compared to last year.